Chunxiao Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chunxiao Fu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alastair Mark Thompson
Department of Surgery, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA
18 shared publications - Amanda L. Rinkenbaugh
Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
18 shared publications - Banu K. Arun
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
18 shared publications - Clinton Yam
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
18 shared publications - Elizabeth E. Ravenberg
Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
18 shared publications - Emily Powell
Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
18 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Copy number summary of PDX collection
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Copy number summary of PDX collection
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Subtype coefficients for longitudinal PDX models
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Subtype coefficients for longitudinal PDX models
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Association of tumor characteristics with take rate and PDX model growth
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Association of tumor characteristics with take rate and PDX model growth
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Triple-negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogeneity characteristic of TNBC. To that end, we established a biobank of 92 orthotopic patient-derived xenograft (PDX) models of TNBC from the tumors of 75 patients enrolled in A Robust TNBC Evaluation fraMework to Improve Survival clinical trial (ARTEMIS, NCT02276443), including 12 longitudinal sets generated from serial patient biopsies collected throughout NACT treatment and from metastatic disease. Models were established from both chemosensitive and chemoresistant tumors, and nearly 30% of the PDX models were capable of metastasizing to the lungs. Comprehensive molecular profiling demonstrated conservation of genomes and transcriptomes between patient and corresponding PDX tumors, with representation of all major transcriptional subtypes. Transcriptional changes observed in the longitudinal PDX models highlighted dysregulation in pathways associated with DNA integrity, extracellular matrix interactions, the ubiquitin–proteasome system, epigenetics, and inflammatory signaling. These alterations revealed a complex network of adaptations associated with chemoresistance. Overall, this PDX biobank provides a valuable tool for tackling the most pressing issues facing the clinical management of TNBC.Significance:The development of a patient-derived xenograft biobank that comprehensively captures the genomic and transcriptional diversity of triple-negative breast cancer promises to be a robust resource to investigate and overcome chemoresistance and metastasis.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Triple-negative breast cancer (TNBC) that fails to respond to neoadjuvant chemotherapy (NACT) can be lethal. Developing effective strategies to eradicate chemoresistant disease requires experimental models that recapitulate the heterogeneity characteristic of TNBC. To that end, we established a biobank of 92 orthotopic patient-derived xenograft (PDX) models of TNBC from the tumors of 75 patients enrolled in A Robust TNBC Evaluation fraMework to Improve Survival clinical trial (ARTEMIS, NCT02276443), including 12 longitudinal sets generated from serial patient biopsies collected throughout NACT treatment and from metastatic disease. Models were established from both chemosensitive and chemoresistant tumors, and nearly 30% of the PDX models were capable of metastasizing to the lungs. Comprehensive molecular profiling demonstrated conservation of genomes and transcriptomes between patient and corresponding PDX tumors, with representation of all major transcriptional subtypes. Transcriptional changes observed in the longitudinal PDX models highlighted dysregulation in pathways associated with DNA integrity, extracellular matrix interactions, the ubiquitin–proteasome system, epigenetics, and inflammatory signaling. These alterations revealed a complex network of adaptations associated with chemoresistance. Overall, this PDX biobank provides a valuable tool for tackling the most pressing issues facing the clinical management of TNBC.Significance:The development of a patient-derived xenograft biobank that comprehensively captures the genomic and transcriptional diversity of triple-negative breast cancer promises to be a robust resource to investigate and overcome chemoresistance and metastasis.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Histological comparison of patient and PDX samples from longitudinal sets
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Histological comparison of patient and PDX samples from longitudinal sets
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Histological comparison of patient and PDX samples from longitudinal sets
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Histological comparison of patient and PDX samples from longitudinal sets
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Summary of available data for longitudinal PDX sets
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Summary of available data for longitudinal PDX sets
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Summary of conservation scores between patient and PDX samples
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Summary of conservation scores between patient and PDX samples
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Subtype coefficients for each PDX models underscores TNBC heterogeneity
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
Subtype coefficients for each PDX models underscores TNBC heterogeneity
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
PDX characteristics and associated patient demographics
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
PDX characteristics and associated patient demographics